Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899639 | 1.00 | TSHR (0.53) | TSHRLOXL2TP53SMN1; SMN2RAB9A | |
| SCHEMBL7471066 | 0.91 | POLB (0.50) | TSHRLOXL2TP53SMN1; SMN2RAB9A | |
| SCHEMBL11555896 | 0.87 | MEN1 (0.47) | TSHRTP53SMN1; SMN2RAB9ANPSR1 | |
| SCHEMBL9315162 | 0.87 | CYP1A2 (0.60) | TSHRLOXL2TP53SMN1; SMN2RAB9A | |
| SCHEMBL29571134 | 0.87 | CYP1A2 (0.60) | TSHRLOXL2TP53SMN1; SMN2RAB9A | |
| SCHEMBL20979533 | 0.84 | LOXL2 (0.56) | TSHRLOXL2TP53SMN1; SMN2RAB9A | |
| SCHEMBL12307633 | 0.84 | TSHR (0.52) | TSHRLOXL2TP53SMN1; SMN2RAB9A | |
| SCHEMBL21415466 | 0.84 | TSHR (0.52) | TSHRLOXL2TP53SMN1; SMN2RAB9A | |
| SCHEMBL11675981 | 0.82 | SMN1; SMN2 (0.49) | TSHRTP53SMN1; SMN2RAB9ANPSR1 | |
| SCHEMBL5316103 | 0.82 | TSHR (0.60) | TSHRLOXL2TP53SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-28 | — | — | US | disclosed |
| EP-4514802-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-03-05 | — | — | EP | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023208986-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-02 | — | — | WO | disclosed |
| CN-113801151-B | Condensed ring aromatic compound and application thereof | 北京八亿时空液晶科技股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023102140-A1 | TMPRSS2 INHIBITORS AND METHODS OF USE | TOPSPIN THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| CN-115151553-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-113801151-A | Fused ring aromatic compound and application thereof | 北京八亿时空液晶科技股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| WO-2021143923-A1 | BORONIC ACID DERIVATIVES | 首药控股(北京)股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| WO-2021143923-A1 | BORONIC ACID DERIVATIVES | 首药控股(北京)股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| US-20060063772-A1 | New compounds | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| WO-2006014185-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | WO | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| EP-1536790-A2 | OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | AstraZeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040132726-A1 | heterocyclic compounds, e.g., 4-(5-m-Tolyl-[1,2,4]oxadiazol-3-ylmethyl)-piperazine-1-carboxylic acid ethyl ester; treatment of mGluR5 receptor-mediated disorders, particularly neurological disorders, psychiatric disorders, acute and chronic pain. | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014370-A2 | OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| CN-1160397-A | Azole deriv. | YAMANOUCHI PHARMA CO LTD (JP) | 1997-09-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | TSHR 4088/4885LOXL2 3001/4885TP53 2732/4885 |
| US-20040132726-A1 | heterocyclic compounds, e.g., 4-(5-m-Tolyl-[1,2,4]oxadiazol-3-ylmethyl)-piperazine-1-carboxylic acid ethyl ester; treatment of mGluR5 receptor-mediated disorders, particularly neurological disorders, psychiatric disorders, acute and chronic pain. | GRM5, GRIK5, GRM1 | TSHR 713/4885LOXL2 2398/4885TP53 4855/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | TSHR 895/4885LOXL2 3040/4885TP53 4878/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | TSHR 2355/4885LOXL2 3342/4885TP53 503/4885 |
| US-20060063772-A1 | New compounds | NPY4R, RPS4X, P2RX4 | TSHR 967/4885LOXL2 3146/4885TP53 2026/4885 |
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, TGFBR2 | TSHR 1578/4885LOXL2 535/4885TP53 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.